Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 12:53pm EDT

By Donato Paolo Mancini

Novartis AG's (NOVN.EB) closed higher on Thursday after jumping on news of a ruling that suggested that market exclusivity for the company's multiple-sclerosis blockbuster drug Gilenya in the U.S. will likely be extended.

"A favorable resolution of the dosage regimen patent litigation" may lengthen the period in which the drug is free from generic competition, according to a Novartis document seen by Dow Jones Newswires.

The note was sent out at around midday Thursday, two analysts told Dow Jones, and shares started climbing around that time. One of the analysts said the market wasn't expecting the decision, so that sent the share price up.

According to the document, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office issued a decision upholding the validity of the dosage-regimen patent on Wednesday. The decision can be appealed, the document said.

Gilenya had sales of $3.19 billion in 2017, according to the company's annual report.

Novartis said it was pleased with the decision, and that it expected to maintain exclusivity until August 2019.

Shares closed up 4.1% at CHF78.94.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
08:46aAmphastar to Get $59.9 Million in Settlement With Momenta, Sandoz -- Update
DJ
07:38aAmphastar to Get $59.9 Million in Settlement With Momenta, Sandoz
DJ
06/18NOVARTIS : New analysis of Novartis data confirms that Cosentyx demonstrates dur..
AQ
06/17NOVARTIS : New Sandoz biosimilar adalimumab data confirms switching from referen..
AQ
06/17NOVARTIS : New analysis of Novartis data confirms that Cosentyx® demonstrates du..
PU
06/14NOVARTIS : New Sandoz biosimilar adalimumab data confirms switching from referen..
PU
06/14NOVARTIS : continues to innovate in CML with long-term treatment-free remission ..
GL
06/13NOVARTIS : Cosentyx first to show efficacy in all key manifestations of psoriati..
AQ
06/13NOVARTIS : Three quarters of people living with axial spondyloarthritis struggle..
PU
06/12NOVARTIS : Cosentyx® provides long-lasting inhibition of radiographic progressio..
GL
More news
Financials ($)
Sales 2019 46 775 M
EBIT 2019 12 309 M
Net income 2019 8 566 M
Debt 2019 15 709 M
Yield 2019 3,30%
P/E ratio 2019 21,89
P/E ratio 2020 19,96
EV / Sales 2019 5,10x
EV / Sales 2020 4,80x
Capitalization 223 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 90,6 $
Spread / Average Target 2,5%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS23.07%220 893
JOHNSON & JOHNSON8.05%348 981
PFIZER-1.76%233 072
ROCHE HOLDING LTD.14.56%227 848
MERCK AND COMPANY9.02%206 641
ELI LILLY AND COMPANY-2.00%113 364